vestimИзвестия Национальной академии наук Беларуси. Серия медицинских наукProceedings of the National Academy of Sciences of Belarus, Medical series1814-60232524-2350The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1814-6023-2024-21-1-68-78vestim-955Research ArticleКЛИНИЧЕСКАЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАCLINICAL AND EXPERIMENTAL MEDICINEЭффективность и безопасность первичного и повторного курсов терапии болезни Паркинсона аутологичными мезенхимальными стромальными клетками в долгосрочном периодеEfficacy and safety of primary and repeated therapy courses of Parkinson’s disease with autologous mesenchymal stromal cells in the long-term periodЧижикВ. А.ChуzhуkV. A.

Чижик Вероника Александровна ‒ ассистент

ул. П. Бровки, 3/3, 220013, г. Минск

Veranika A. Chуzhуk – Assistant

3/3, P. Browka Str., 220013, Minsk

chyzhykva@gmail.comСелицкийМ. М.SialitskiМ. М.

Селицкий Михаил Михайлович ‒ канд. мед. наук, доцент

ул. П. Бровки, 3/3, 220013, г. Минск

Mikhail M. Sialitski – Ph. D. (Med.), Associate Professor

3/3, P. Browka Str., 220013, Minsk

m_sialitski@tut.byПономаревВ. В.PonomarevV. V.

Пономарев Владимир Владимирович ‒ д-р мед. наук, профессор, заведующий кафедрой

ул. П. Бровки, 3/3, 220013, г. Минск

Vladimir V. Ponomarev – D. Sc. (Med.), Professor, Head of the Department.

3/3, P. Browka Str., 220013, Minsk

professor.ponomarev@gmail.comИнститут повышения квалификации и переподготовки кадров здравоохранения УО «Белорусский государственный медицинский университет»Institute of Advanced Training and Retraining of Healthcare Personnel of Educational Institution “Belarusian State Medical University”2024040320242116878Copyright © Чижик В.А., Селицкий М.М., Пономарев В.В., 20242024Чижик В.А., Селицкий М.М., Пономарев В.В.Chуzhуk V.A., Sialitski М.М., Ponomarev V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestimed.belnauka.by/jour/article/view/955

Болезнь Паркинсона (БП) – это хроническое неуклонно прогрессирующее заболевание. Лечение БП в настоящее время носит симптоматический характер. Одним из перспективных направлений в разработке терапии, изменяющей течение БП, является использование аутологичных мультипотентных мезенхимальных стромальных клеток (ММСК). Несмотря на обнадеживающие результаты различных доклинических и клинических испытаний в отношении эффективности клеточной терапии и ее доказанную безопасность, остаются открытыми такие вопросы клеточной терапии, как выбор оптимального пути введения, дозы и частоты курсов лечения.

В настоящем исследовании проведена оценка динамики моторных и немоторных проявлений БП после первого и второго курсов клеточной терапии с использованием ММСК системным и тандемным методами в долгосрочном периоде наблюдения. Выявлен положительный эффект клеточной терапии на динамику моторных и немоторных симптомов у пациентов с БП в течение в среднем 6 мес. после проведения одного курса лечения ММСК. Повторный курс лечения ММСК имеет схожую с первым курсом эффективность и безопасность и может быть применен для замедления прогрессирования БП на более длительный срок.

Parkinson’s disease (PD) is a chronic progressive disease. Currently, PD treatment is symptomatic. One of the promising directions changing the PD therapy course is the use of autologous multipotent mesenchymal stromal cells (MMSCs). Despite the encouraging results in various preclinical and clinical trials and proven safety, the cell therapy questions remain open, such as the choice of an optimal route of administration, dose, and frequency of treatment courses.

In the present study, the dynamics of PD motor and non-motor symptoms was assessed after the first and second cell therapy courses using MMSC injections via systemic and tandem methods during a long-term period. A positive therapy effect on the dynamics of motor and non-motor symptoms in patients with PD was revealed for an average of 6 months after one MMSC treatment course. The repeated MMSC treatment course has similar efficacy and safety to the first course and can be used to slow down the PD progression for a longer period.

аутологичные мультипотентные мезенхимальные стромальные клеткиболезнь Паркинсонадолгосрочный период клеточной терапииповторные курсы клеточной терапиимоторные симптомынемоторные симптомыautologous multipotent mesenchymal stromal cellsParkinson’s diseaselong-term periodrepeated cell therapy coursesmotor symptomsnon-motor symptomsReferencesSchrag, A. How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population / A. Schrag, M. Jahanshahi, N. Quinn // Mov. Disord. ‒ 2000. ‒ Vol. 15, N 6. – P. 1112–1118. https://doi.org/10.1002/1531-8257(200011)15:63.0.co;2-aSchrag A., Jahanshahi M., Quinn N. How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Movement Disorders, 2000, vol. 15, pp. 1112–1118. https://doi.org/10.1002/1531-8257(200011)15:63.0.co;2-aAggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease / W. Zhang [et al.] // FASEB J. – 2005. – Vol. 19, N 6. – P. 533–542. https://doi.org/10.1096/fj.04-2751comZhang W., Wang T., Pei Zh., D. Miller S., Wu X., Block M. [et al.]. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB Journal, 2005, vol. 19, no. 6, pp. 533–542. https://doi.org/10.1096/fj.04-2751comЛевин, О. С. Болезнь Паркинсона / О. С. Левин, Н. В. Федорова. ‒ 5-е изд. ‒ М.: МЕДпресс-информ, 2015. – 352 с.Levin O. S., Fedorova N. V. Parkinson’s disease. 5th ed. Moscow, MEDpress-inform Publ., 2012. 352 p. (in Russian).Chaudhuri, K. R. Non-motor symptoms of Parkinson’s disease: diagnosis and management / K. R. Chaudhuri, D. G. Healy, A. H. Schapira // Lancet Neurol. – 2006. – Vol. 5, N 3. – P. 235–245. https://doi.org/10.1016/S1474-4422(06)70373-8Chaudhuri K. R., Healy D. G., Schapira A. H. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurology, 2006, vol. 5, no. 3, pp. 235–245. https://doi.org/10.1016/S1474-4422(06)70373-8The acute brain response to levodopa heralds dyskinesias in Parkinson disease / D. M. Herz [et al.] // Ann. Neurol. – 2014. ‒ Vol. 75, N 6. – P. 829–836. https://doi.org/10.1002/ana.24138Herz D. M., Haagensen B. N., Christensen M. S., Madsen K. H., Rowe J. B., Løkkegaard A., Siebner H. R. The acute brain response to levodopa heralds dyskinesias in Parkinson disease. Annals of Neurology, 2014, vol. 75, no. 6, pp. 829–836. https://doi.org/10.1002/ana.24138Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson’s disease / M. Salama [et al.] // Exp. Therapeut. Med. – 2017. – Vol. 13, N 3. – P. 976‒982. https://doi.org/10.3892/etm.2017.4073Salama M., Sobh M., Emam M., Abdalla A., Sabry D., El-Gamal M. [et al.]. Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson’s disease. Experimental and Therapeutic Medicine, 2017, vol. 13, no. 3, pp. 976‒982. https://doi.org/10.3892/etm.2017.4073Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson’s disease / D. Chen [et al.] // J. Neurosci. Res. – 2017. – Vol. 95, N 3. – P. 907‒917. https://doi.org/10.1002/jnr.23879Chen D., Fu W., Zhuang W., Lv C., Li F., Wang X. J. Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson’s disease. Journal of Neuroscience Research, 2017, vol. 95, no. 3, pp. 907‒917. https://doi.org/10.1002/jnr.23879Chyzhyk, V. Assessment of non-motor symptoms of Parkinson’s disease in the long-term follow-up after the cell therapy [Electronic resource] / V. Chyzhyk, A. Boika, V. Ponomarev. ‒ Mode of access: https://www.mdsabstracts.org/abstract/assessment-of-non-motor-symptoms-of-parkinsons-disease-in-the-long-term-follow-up-after-the-cell-therapy. ‒ Date of access: 06.07.2023.Chyzhyk V., Boika A., Ponomarev V. Assessment of non-motor symptoms of Parkinson’s disease in the long-term follow-up after the cell therapy. Available at: https://www.mdsabstracts.org/abstract/assessment-of-non-motor-symptomsof-parkinsons-disease-in-the-long-term-follow-up-after-the-cell-therapy (accessed 06.07.2023).Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials / J. D. Glass [et al.] // Neurology. – 2016. – Vol. 87, N 4. – P. 392–400. https://doi.org/10.1212/WNL.0000000000002889Glass J. D., Hertzberg V. S., Boulis N. M., Riley J., Federici T., Polak M. [et al.]. Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials. Neurology, 2016, vol. 87, no. 4, pp. 392–400. https://doi.org/10.1212/WNL.0000000000002889Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials / P. Petrou [et al.] // JAMA Neurol. – 2016. – Vol. 73, N 3. – P. 337–344. https://doi.org/10.1001/jamaneurol.2015.4321Petrou P., Gothelf Y., Argov Z., Gotkine M., Levy Y. S., Kassis I. [et al.]. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurology, 2016, vol. 73, no. 3, pp. 337–344. https://doi.org/10.1001/jamaneurol.2015.4321NurOwn, phase 2, randomized, clinical trial in patients with ALS / J. D. Berry [et al.] // Neurology. – 2019. – Vol. 93, N 24. – P. e2294–e2305. https://doi.org/10.1212/WNL.0000000000008620Berry J. D., Cudkowicz M. E., Windebank A. J., Staff N. P., Owegi M., Nicholson K. [et al.]. NurOwn, phase 2, randomized, clinical trial in patients with ALS. Neurology, 2019, vol. 93, no. 24, pp. e2294–e2305. https://doi.org/10.1212/WNL.0000000000008620Long-term clinical and immunological effects of repeated mesenchymal stem cell injections in patients with progressive forms of multiple sclerosis / P. Petrou [et al.] // Front. Neurol. – 2021. – Vol. 12. – Art. 639315. https://doi.org/10.3389/fneur.2021.639315Petrou P., Kassis I., Ginzberg A., Halimi M., Yaghmour N., Abramsky O., Karussis D. Long-term clinical and immunological effects of repeated mesenchymal stem cell injections in patients with progressive forms of multiple sclerosis. Frontiers of Neurology, 2021, vol. 12, art. 639315. https://doi.org/10.3389/fneur.2021.639315Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: Safety and efficacy of the 100/3 guideline / J. Vaquero [et al.] // Cytotherapy. – 2018. – Vol. 20, N 6. – P. 806–819. https://doi.org/10.1016/j.jcyt.2018.03.032Vaquero J., Zurita M., Rico M. A., Aguayo C., Bonilla C., Marin E. [et al.]. Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: Safety and efficacy of the 100/3 guideline. Cytotherapy, 2018, vol. 20, no. 6, pp. 806–819. https://doi.org/10.1016/j.jcyt.2018.03.032Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases / A. J. Hughes [et al.] // J. Neurol. Neurosurg. Psychiatry. ‒ 1992. – Vol. 55, N 3. – Р. 181‒184. https://doi.org/10.1136/jnnp.55.3.181Hughes A. J., Daniel S. E., Kilford L., Lees A. J. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery, and Psychiatry, 1992, vol. 55, no. 3, pp. 181‒184. https://doi.org/10.1136/jnnp.55.3.181Hoehn, M. M. Parkinsonism: onset, progression, and mortality / M. M. Hoehn, M. Yahr // Neurology. – 1967. – Vol. 17, N 5. – Р. 427–442. https://doi.org/10.1212/wnl.17.5.427Hoehn M. M. Parkinsonism: onset, progression, and mortality. Neurology, 1967, vol. 17, no. 5, pp. 427–442. https://doi.org/10.1212/wnl.17.5.427Thuy, C. Vu. Progression of motor and nonmotor features of Parkinson’s disease and their response to treatment / C. Vu Thuy, J. G. Nutt, N. H. G. Holford // Br. J. Clin. Pharmacol. – 2012. – Vol. 74, N 2. – P. 267–283. https://doi.org/10.1111/j.1365-2125.2012.04192.xThuy C. Vu, Nutt J. G., Holford N. H. G. Progression of motor and nonmotor features of Parkinson’s disease and their response to treatment. British Journal of Clinical Pharmacology, 2012, vol. 74, no. 2, pp. 267–283. https://doi.org/10.1111/j.1365-2125.2012.04192.xParacrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives / X. Liang [et al.] // Cell Transplant. – 2014. – Vol. 23, N 9. – P. 1045–1059. https://doi.org/10.3727/096368913X667709Liang X., Ding Y., Zhang Y., Tse H. F., Lian Q. Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives. Cell Transplantation, 2014, vol. 23, no. 9, pp. 1045–1059. https://doi.org/10.3727/096368913X667709Induced pluripotent stem cell-derived mesenchymal stem cells activate quiescent T cells and elevate regulatory T cell response via NF-κB in allergic rhinitis patients / X.-L. Fan [et al.] // Stem Cell Res. Ther. – 2018. – Vol. 9, N 1. – Art. 170. https://doi.org/10.1186/s13287-018-0896-zFan X.-L., Zeng Q.-X., Li X., Li C.-L., Xu Z.-B., Deng X.-Q., Shi J., Chen D., Zheng S. G., Fu Q.-L. Induced pluripotent stem cell-derived mesenchymal stem cells activate quiescent T cells and elevate regulatory T cell response via NF-κB in allergic rhinitis patients. Stem Cell Research & Therapy, 2018, vol. 9, no. 1, art. 170. https://doi.org/10.1186/s13287-018-0896-zGreen, D. R. Mitochondria and apoptosis / D. R. Green, J. C. Reed // Science. – 1998. – Vol. 281, N 5381. – P. 1309–1312. https://doi.org/10.1126/science.281.5381.1309Green D. R., Reed J. C. Mitochondria and apoptosis. Science, 1998, vol. 281, no. 5381, pp. 1309–1312. https://doi.org/10.1126/science.281.5381.1309Human bone marrow mesenchymal stem cells protect catecholaminergic and serotonergic neuronal perikarya and transporter function from oxidative stress by the secretion of glial-derived neurotrophic factor / A. L. Whone [et al.] // Brain Res. – 2012. – Vol. 1431. – P. 86–96. https://doi.org/10.1016/j.brainres.2011.10.038Whone A. L., Kemp K., Sun M., Wilkins A., Scolding N. J. Human bone marrow mesenchymal stem cells protect catecholaminergic and serotonergic neuronal perikarya and transporter function from oxidative stress by the secretion of glial-derived neurotrophic factor. Brain Research, 2012, vol. 1431, pp. 86–96. https://doi.org/10.1016/j.brainres.2011.10.038Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the Warburg effect by secreting STC1 / S. Ohkouchi [et al.] // Mol. Ther. – 2012. – Vol. 20, N 2. – P. 417–423. https://doi.org/10.1038/mt.2011.259Ohkouchi S., Block G. J., Katsha A. M., Kanehira M., Ebina M., Kikuchi T., Saijo Y., Nukiwa T., Prockop D. J. Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the Warburg effect by secreting STC. Molecular Therapy, 2012, vol. 20, no. 2, pp. 417–423. https://doi.org/10.1038/mt.2011.259Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury / M. N. Islam [et al.] // J. Nat. Med. – 2012. – Vol. 18, N 5. – P. 759–765. https://doi.org/10.1038/nm.2736Islam M. N., Das S. R., Emin M. T., Wei M., Sun L., Westphalen K., Rowlands D. J., Quadri S. K., Bhattacharya S., Bhattacharya J. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Journal of Natural Medicines, 2012, vol. 18, no. 5, pp. 759–765. https://doi.org/10.1038/nm.2736de Becker, A. Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy? / A. de Becker, I. V. Riet // World J. Stem Cells. – 2016. – Vol. 8, N 3. – P. 73–87. https://doi.org/10.4252/wjsc.v8.i3.73De Becker A., Riet I. V. Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy? World Journal of Stem Cells, 2016, vol. 8, no. 3, pp. 73–87. https://doi.org/10.4252/wjsc.v8.i3.73The critical role of apoptosis in mesenchymal stromal cell therapeutics and implications in homeostasis and normal tissue repair / Ch. Giacomini [et al.] // Cell Mol. Immunol. – 2023. – Vol. 20, N 6. – P. 570–582. https://doi.org/10.1038/s41423-023-01018-9Giacomini Ch., Granéli C., Hicks R., Dazzi F. The critical role of apoptosis in mesenchymal stromal cell therapeutics and implications in homeostasis and normal tissue repair. Cellular and Molecular Immunology, 2023, vol. 20, no. 6, pp. 570–582. https://doi.org/10.1038/s41423-023-01018-9Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells / S. F. H. de Witte [et al.] // Stem Cells. – 2018. – Vol. 36, N 4. – P. 602–615. https://doi.org/10.1002/stem.2779de Witte S. F. H., Luk F., Sierra Parraga J. M., Gargesha M., Merino A., Korevaar S. S. [et al.]. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. Stem Cells, 2018, vol. 36, no. 4, pp. 602–615. https://doi.org/10.1002/stem.2779

The authors declare that there are no conflicts of interest present.